SG Americas Securities’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$600M Buy
652,281
+396,357
+155% +$402M 0.65% 21
2025
Q4
$275M Buy
255,924
+243,439
+1,950% +$233M 0.35% 31
2025
Q3
$9.53M Sell
12,485
-945
-7% -$703K 0.03% 334
2025
Q2
$10.5M Sell
13,430
-54,638
-80% -$42.5M 0.04% 296
2025
Q1
$56.2M Buy
68,068
+65,102
+2,195% +$54.2M 0.18% 73
2024
Q4
$2.29M Sell
2,966
-43,206
-94% -$35.8M 0.01% 559
2024
Q3
$40.9M Buy
46,172
+19,064
+70% +$17.1M 0.15% 69
2024
Q2
$24.5M Sell
27,108
-153,083
-85% -$122M 0.14% 141
2024
Q1
$140M Buy
180,191
+155,592
+633% +$111M 0.67% 21
2023
Q4
$14.3M Sell
24,599
-108,520
-82% -$63.3M 0.13% 145
2023
Q3
$71.5M Buy
133,119
+100,675
+310% +$51.9M 0.82% 13
2023
Q2
$15.2M Sell
32,444
-76,939
-70% -$32.3M 0.12% 115
2023
Q1
$37.6M Buy
109,383
+100,638
+1,151% +$33.9M 0.44% 33
2022
Q4
$3.2M Sell
8,745
-12,351
-59% -$4.38M 0.04% 387
2022
Q3
$6.82M Sell
21,096
-8,050
-28% -$2.55M 0.08% 212
2022
Q2
$9.45M Buy
29,146
+13,249
+83% +$3.98M 0.1% 160
2022
Q1
$4.55M Sell
15,897
-37,107
-70% -$9.55M 0.03% 462
2021
Q4
$14.6M Buy
53,004
+39,193
+284% +$9.94M 0.08% 191
2021
Q3
$3.19M Sell
13,811
-29,903
-68% -$7.38M 0.02% 873
2021
Q2
$10M Sell
43,714
-89,765
-67% -$18M 0.05% 346
2021
Q1
$24.9M Buy
133,479
+103,371
+343% +$20.2M 0.13% 140
2020
Q4
$5.08M Sell
30,108
-18,378
-38% -$2.74M 0.03% 500
2020
Q3
$7.18M Buy
48,486
+36,455
+303% +$5.64M 0.05% 247
2020
Q2
$1.98M Sell
12,031
-55,963
-82% -$8.59M 0.02% 848
2020
Q1
$9.43M Buy
67,994
+63,191
+1,316% +$8.68M 0.09% 209
2019
Q4
$631K Sell
4,803
-147,371
-97% -$17.1M 0.01% 1586
2019
Q3
$17M Buy
152,174
+50,274
+49% +$5.6M 0.14% 125
2019
Q2
$11.3M Buy
101,900
+77,755
+322% +$9.16M 0.08% 241
2019
Q1
$3.13M Sell
24,145
-82,116
-77% -$9.99M 0.03% 619
2018
Q4
$12.3M Sell
106,261
-62,013
-37% -$6.93M 0.11% 164
2018
Q3
$18.1M Buy
168,274
+130,637
+347% +$13.1M 0.13% 148
2018
Q2
$3.21M Sell
37,637
-65,212
-63% -$5.36M 0.03% 648
2018
Q1
$7.96M Sell
102,849
-84,542
-45% -$6.81M 0.06% 250
2017
Q4
$15.8M Buy
187,391
+169,020
+920% +$14.4M 0.15% 112
2017
Q3
$1.57M Sell
18,371
-73,799
-80% -$6.05M 0.01% 943
2017
Q2
$7.59M Sell
92,170
-61,898
-40% -$5.05M 0.07% 282
2017
Q1
$13M Sell
154,068
-19,442
-11% -$1.56M 0.11% 160
2016
Q4
$12.8M Buy
173,510
+119,752
+223% +$8.92M 0.11% 177
2016
Q3
$4.32M Sell
53,758
-78,653
-59% -$6.3M 0.05% 395
2016
Q2
$10.4M Sell
132,411
-414,850
-76% -$31.2M 0.07% 197
2016
Q1
$39.4M Buy
547,261
+539,846
+7,280% +$40.8M 0.28% 50
2015
Q4
$625K Sell
7,415
-75,211
-91% -$6.24M ﹤0.01% 1459
2015
Q3
$5.25M Buy
82,626
+46,866
+131% +$3.96M 0.03% 360
2015
Q2
$2.99M Sell
35,760
-82,080
-70% -$6.25M 0.02% 554
2015
Q1
$8.56M Sell
117,840
-402,493
-77% -$28.7M 0.05% 256
2014
Q4
$35.9M Buy
520,333
+335,269
+181% +$22.6M 0.18% 110
2014
Q3
$12M Buy
185,064
+52,145
+39% +$3.3M 0.07% 281
2014
Q2
$8.26M Sell
132,919
-623,859
-82% -$37.2M 0.05% 391
2014
Q1
$44.5M Sell
756,778
-161,951
-18% -$9.04M 0.19% 117
2013
Q4
$46.9M Sell
918,729
-80,983
-8% -$4.06M 0.2% 114
2013
Q3
$50.3M Buy
999,712
+142,674
+17% +$7.47M 0.21% 97
2013
Q2
$42.1M Buy
+857,038
New +$46.6M 0.21% 98

Other funds holding LLY

SG Americas Securities's LLY Position: Q1 2026 in Review

SG Americas Securities increased its Eli Lilly (LLY) stake by 155% in Q1 2026, buying an estimated $402M and bringing the position to 652,281 shares worth $600M. The position accounts for 0.65% of the portfolio, ranked #21.

SG Americas Securities first reported a position in LLY in Q2 2013 and has held it in 52 quarters since. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • SG Americas Securities held 652,281 shares of Eli Lilly worth $600M as of Q1 2026.
  • SG Americas Securities bought 396,357 Eli Lilly shares in Q1 2026, an estimated $402M.
  • Eli Lilly made up 0.65% of SG Americas Securities's portfolio in Q1 2026, its #21 holding.
  • SG Americas Securities first reported a position in Eli Lilly in Q2 2013 and has held it in 52 quarters since.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.